Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
455.75
+2.01 (+0.44%)
Streaming Delayed Price
Updated: 1:15 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
69
70
Next >
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
↗
April 15, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Government
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades
↗
April 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Stocks
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
↗
April 11, 2025
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation.
Via
Benzinga
Topics
Artificial Intelligence
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
April 11, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
↗
April 11, 2025
Via
The Motley Fool
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
↗
April 10, 2025
Via
The Motley Fool
Topics
Economy
Government
World Trade
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
↗
April 09, 2025
Via
The Motley Fool
Topics
Government
Is Vertex Pharmaceuticals Stock a Buy?
↗
April 08, 2025
Via
The Motley Fool
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
↗
April 07, 2025
A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited.
Via
Benzinga
Topics
Stocks
World Trade
Vertex to Announce First Quarter 2025 Financial Results on May 5th
April 07, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
↗
April 07, 2025
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.
Via
Benzinga
2 Stocks to Buy if You're Worried About a Recession
↗
April 07, 2025
Via
The Motley Fool
Topics
Economy
Government
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
April 07, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...
Via
StockStory
Topics
Artificial Intelligence
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm
↗
April 06, 2025
Via
The Motley Fool
Topics
Earnings
Economy
Government
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
↗
April 04, 2025
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Via
Benzinga
Topics
Government
World Trade
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
↗
April 04, 2025
Via
The Motley Fool
Topics
Economy
Energy
Government
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
April 03, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...
Via
StockStory
Topics
Artificial Intelligence
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
↗
April 02, 2025
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
Via
Stocktwits
Topics
ETFs
Government
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
↗
April 01, 2025
Via
Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
↗
March 31, 2025
Via
Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
↗
March 31, 2025
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.
Via
Benzinga
Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
↗
March 29, 2025
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout.
Via
Chartmill
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
March 28, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
↗
March 28, 2025
Via
Benzinga
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
↗
March 28, 2025
Via
The Motley Fool
Topics
Economy
Government
Stocks
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
↗
March 27, 2025
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.
Via
Investor's Business Daily
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
↗
March 21, 2025
Via
Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
March 20, 2025
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Via
StockStory
Topics
Artificial Intelligence
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
↗
March 19, 2025
Via
The Motley Fool
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
March 19, 2025
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
